TY - JOUR AU - Guo, Jun AU - Ma, Jianhui AU - Sun, Yan AU - Qin, Shukui AU - Ye, Dingwei AU - Zhou, Fangjian AU - He, Zhisong AU - Sheng, Xinan AU - Bi, Feng AU - Cao, Dengfeng AU - Chen, Yingxia AU - Huang, Yiran AU - Liang, Houjie AU - Liu, Jiwei AU - Liu, Wenchao AU - Pan, Yueyin AU - Shu, Yongqian AU - Song, Xin AU - Wang, Weibo AU - Wang, Xiuwen AU - Wu, Xiaoan AU - Xie, Xiaodong AU - Yao, Xin AU - Yu, Shiying AU - Zhang, Yanqiao AU - Zhou, Aiping AU - Renal Cell Carcinoma Committee, written on behalf of CSCO PY - 2015 TI - Chinese guidelines on the management of renal cell carcinoma (2015 edition) JF - Chinese Clinical Oncology; Vol 5, No 1 (February 29, 2016): Chinese Clinical Oncology Y2 - 2015 KW - N2 - The guideline was established by the kidney cancer panel under the Chinese Society of Clinical Oncology (CSCO) in accordance with the basic principles of evidence-based medicine ( Table 1 ) and the clinical practices on renal cancer in China, based on the real conditions of China, and by referring to the USA NCCN Clinical Practice Guidelines in Oncology-Kidney Cancer (1) and the European Association of Urology (EAU) Guidelines on Renal Cell Carcinoma (2). The renal cancer referred in these guidelines is the renal cell carcinoma (RCC) and does not include various tumors originated from renal interstitium and renal pelvis/urothelial system. UR - https://cco.amegroups.org/article/view/8308